Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT

Tomomi Nobashi, Lucia Baratto, Sunil A. Reddy, Sandhya Srinivas, Akira Toriihara, Negin Hatami, Thomas K. Yohannan, Erik Mittra

Research output: Contribution to journalArticle

Abstract

Purpose To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and immune-related adverse events (IRAE) with 18 F-FDG PET/CT can predict the efficacy and outcome of immunotherapy. Methods Forty patients who underwent 18 F-FDG-PET/CT scans before and after therapy with immune checkpoint inhibitors from December 2013 to December 2016 were retrospectively enrolled (malignant melanoma, n = 21; malignant lymphoma, n = 11; renal cell carcinoma, n = 8). SUVmax of the baseline and first restaging scans were evaluated in tumors, spleen, bone marrow, thyroid and pituitary glands, and were correlated to best overall response in the first year after therapy; IRAE-affected areas were also evaluated. Results Interval change between the baseline and first restaging scans showed that patients with a clinical benefit had a significant decrease in tumor parameters (P < 0.001). All patients with an increase of SUVmax in the thyroid of more than 1.5 (n = 5) on the first restaging scan had a complete response (CR) in 1 year. Patients with CR within 1 year (n = 22) were significantly associated with a favorable long-term outcome (P = 0.002). Nine patients with IRAE findings had CR at final evaluation. Among IRAE, thyroiditis was seen significantly earlier than arthritis (P = 0.040). Conclusions The decrease of tumor parameters at early time-point PET scans was seen in patients with immunotherapy who had clinical benefit within 1 year. PET-detectable IRAE was useful for prediction of a favorable outcome. Early development of thyroiditis may particularly represent an early response indicator to immunotherapy.

Original languageEnglish (US)
Pages (from-to)e272-e279
JournalClinical Nuclear Medicine
Volume44
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Immunotherapy
Lymphocytes
Thyroiditis
Neoplasms
Thyroid Gland
Pituitary Gland
Renal Cell Carcinoma
Positron-Emission Tomography
Arthritis
Melanoma
Lymphoma
Spleen
Bone Marrow
Therapeutics

Keywords

  • F-FDG-PET/CT
  • immune checkpoint inhibitors
  • IRAE
  • outcome
  • tumor response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. / Nobashi, Tomomi; Baratto, Lucia; Reddy, Sunil A.; Srinivas, Sandhya; Toriihara, Akira; Hatami, Negin; Yohannan, Thomas K.; Mittra, Erik.

In: Clinical Nuclear Medicine, Vol. 44, No. 4, 01.04.2019, p. e272-e279.

Research output: Contribution to journalArticle

Nobashi, Tomomi ; Baratto, Lucia ; Reddy, Sunil A. ; Srinivas, Sandhya ; Toriihara, Akira ; Hatami, Negin ; Yohannan, Thomas K. ; Mittra, Erik. / Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. In: Clinical Nuclear Medicine. 2019 ; Vol. 44, No. 4. pp. e272-e279.
@article{82d3921e5c1342118e58451e535a0996,
title = "Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT",
abstract = "Purpose To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and immune-related adverse events (IRAE) with 18 F-FDG PET/CT can predict the efficacy and outcome of immunotherapy. Methods Forty patients who underwent 18 F-FDG-PET/CT scans before and after therapy with immune checkpoint inhibitors from December 2013 to December 2016 were retrospectively enrolled (malignant melanoma, n = 21; malignant lymphoma, n = 11; renal cell carcinoma, n = 8). SUVmax of the baseline and first restaging scans were evaluated in tumors, spleen, bone marrow, thyroid and pituitary glands, and were correlated to best overall response in the first year after therapy; IRAE-affected areas were also evaluated. Results Interval change between the baseline and first restaging scans showed that patients with a clinical benefit had a significant decrease in tumor parameters (P < 0.001). All patients with an increase of SUVmax in the thyroid of more than 1.5 (n = 5) on the first restaging scan had a complete response (CR) in 1 year. Patients with CR within 1 year (n = 22) were significantly associated with a favorable long-term outcome (P = 0.002). Nine patients with IRAE findings had CR at final evaluation. Among IRAE, thyroiditis was seen significantly earlier than arthritis (P = 0.040). Conclusions The decrease of tumor parameters at early time-point PET scans was seen in patients with immunotherapy who had clinical benefit within 1 year. PET-detectable IRAE was useful for prediction of a favorable outcome. Early development of thyroiditis may particularly represent an early response indicator to immunotherapy.",
keywords = "F-FDG-PET/CT, immune checkpoint inhibitors, IRAE, outcome, tumor response",
author = "Tomomi Nobashi and Lucia Baratto and Reddy, {Sunil A.} and Sandhya Srinivas and Akira Toriihara and Negin Hatami and Yohannan, {Thomas K.} and Erik Mittra",
year = "2019",
month = "4",
day = "1",
doi = "10.1097/RLU.0000000000002453",
language = "English (US)",
volume = "44",
pages = "e272--e279",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT

AU - Nobashi, Tomomi

AU - Baratto, Lucia

AU - Reddy, Sunil A.

AU - Srinivas, Sandhya

AU - Toriihara, Akira

AU - Hatami, Negin

AU - Yohannan, Thomas K.

AU - Mittra, Erik

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and immune-related adverse events (IRAE) with 18 F-FDG PET/CT can predict the efficacy and outcome of immunotherapy. Methods Forty patients who underwent 18 F-FDG-PET/CT scans before and after therapy with immune checkpoint inhibitors from December 2013 to December 2016 were retrospectively enrolled (malignant melanoma, n = 21; malignant lymphoma, n = 11; renal cell carcinoma, n = 8). SUVmax of the baseline and first restaging scans were evaluated in tumors, spleen, bone marrow, thyroid and pituitary glands, and were correlated to best overall response in the first year after therapy; IRAE-affected areas were also evaluated. Results Interval change between the baseline and first restaging scans showed that patients with a clinical benefit had a significant decrease in tumor parameters (P < 0.001). All patients with an increase of SUVmax in the thyroid of more than 1.5 (n = 5) on the first restaging scan had a complete response (CR) in 1 year. Patients with CR within 1 year (n = 22) were significantly associated with a favorable long-term outcome (P = 0.002). Nine patients with IRAE findings had CR at final evaluation. Among IRAE, thyroiditis was seen significantly earlier than arthritis (P = 0.040). Conclusions The decrease of tumor parameters at early time-point PET scans was seen in patients with immunotherapy who had clinical benefit within 1 year. PET-detectable IRAE was useful for prediction of a favorable outcome. Early development of thyroiditis may particularly represent an early response indicator to immunotherapy.

AB - Purpose To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and immune-related adverse events (IRAE) with 18 F-FDG PET/CT can predict the efficacy and outcome of immunotherapy. Methods Forty patients who underwent 18 F-FDG-PET/CT scans before and after therapy with immune checkpoint inhibitors from December 2013 to December 2016 were retrospectively enrolled (malignant melanoma, n = 21; malignant lymphoma, n = 11; renal cell carcinoma, n = 8). SUVmax of the baseline and first restaging scans were evaluated in tumors, spleen, bone marrow, thyroid and pituitary glands, and were correlated to best overall response in the first year after therapy; IRAE-affected areas were also evaluated. Results Interval change between the baseline and first restaging scans showed that patients with a clinical benefit had a significant decrease in tumor parameters (P < 0.001). All patients with an increase of SUVmax in the thyroid of more than 1.5 (n = 5) on the first restaging scan had a complete response (CR) in 1 year. Patients with CR within 1 year (n = 22) were significantly associated with a favorable long-term outcome (P = 0.002). Nine patients with IRAE findings had CR at final evaluation. Among IRAE, thyroiditis was seen significantly earlier than arthritis (P = 0.040). Conclusions The decrease of tumor parameters at early time-point PET scans was seen in patients with immunotherapy who had clinical benefit within 1 year. PET-detectable IRAE was useful for prediction of a favorable outcome. Early development of thyroiditis may particularly represent an early response indicator to immunotherapy.

KW - F-FDG-PET/CT

KW - immune checkpoint inhibitors

KW - IRAE

KW - outcome

KW - tumor response

UR - http://www.scopus.com/inward/record.url?scp=85062387258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062387258&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002453

DO - 10.1097/RLU.0000000000002453

M3 - Article

C2 - 30688730

AN - SCOPUS:85062387258

VL - 44

SP - e272-e279

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 4

ER -